Download Free Plant Molecular Farming For The Production Of Next Generation Vaccines And Biologics Prospects And Challenges Book in PDF and EPUB Free Download. You can read online Plant Molecular Farming For The Production Of Next Generation Vaccines And Biologics Prospects And Challenges and write the review.

Infectious diseases are still a major threat to public health. The vaccine remains the most important and safer way of combating infectious diseases. Therefore, there is an urgent need to look for new ways of vaccine generation that can cut down production costs and processing time. The development of rDNA technology allows the expression and purification of proteins in unlimited quantity, thus opening an avenue for the development of protein-based vaccines as a prophylactic measure against infectious diseases. Recombinant therapeutic proteins derived from biological sources, including mammalian cells, microorganisms, suspension cultures, or genetically modified organisms by employing biotechnological processes, are widely used in clinical applications, especially for the treatment and prevention of human or veterinary infections. Since the development of human insulin by utilizing recombinant DNA technology in E. coli in the 1980s, the recombinant therapeutic protein production field has significantly grown and gained major attention. Plant molecular farming, the production of biologics in plant cells or transgenic plants, could offer a cost-effective adaptable strategy to produce biologics, particularly in low-resource settings. Molecular farming-based strategies could provide an alternative strategy to traditional biologics or vaccine production, enabling rapid development, effective deployment, and safe administration of vaccines. The concept of PMF was initially documented three decades back when recombinant growth hormone was produced in tobacco and sunflower plants. Even with such a long history of significant advantages and several proof-of-concept studies, very few plant-derived therapeutic products have been clinically translated. However, the recent progress around the approval of the plant-based biopharmaceutical ZMapp by the FDA, Medicago’s COVID-19 vaccine by Health Canada, and the safety of a few plant-derived vaccines in clinical trials have displayed the potential of a plant platform for biopharmaceutical production. Furthermore, constant efforts are being made with respect to the optimization of expression techniques, downstream processing, and defining standard guidelines for plant products to make an impact of plant-derived products on an array of applications.
Molecular farming in plants is a relatively young subject of sciences. As plants can offer an inexpensive and convenient platform for the large-scale production of recombinant proteins with various functions, the driven force from the giant market for recombinant protein pharmaceuticals and industrial enzymes makes this subject grow and advance very quickly. To summarize recent advances, current challenges and future directions in molecular farming, international authorities were invited to write this book for researchers, teachers and students who are interested in this subject. This book, with the focus on the most advanced cutting-edge breakthroughs, covers all the essential aspects of the field of molecular farming in plants: from expression technologies to downstream processing, from products to safety issues, and from current advances and holdups to future developments.
A single volume collection that surveys the exciting field of plant-made pharmaceuticals and industrial proteins This comprehensive book communicates the recent advances and exciting potential for the expanding area of plant biotechnology and is divided into six sections. The first three sections look at the current status of the field, and advances in plant platforms and strategies for improving yields, downstream processing, and controlling post-translational modifications of plant-made recombinant proteins. Section four reviews high-value industrial and pharmacological proteins that are successfully being produced in established and emerging plant platforms. The fifth section looks at regulatory challenges facing the expansion of the field. The final section turns its focus toward small molecule therapeutics, drug screening, plant specialized metabolites, and plants as model organisms to study human disease processes. Molecular Pharming: Applications, Challenges and Emerging Areas offers in-depth coverage of molecular biology of plant expression systems and manipulation of glycosylation processes in plants; plant platforms, subcellular targeting, recovery, and downstream processing; plant-derived protein pharmaceuticals and case studies; regulatory issues; and emerging areas. It is a valuable resource for researchers that are in the field of plant molecular pharming, as well as for those conducting basic research in gene expression, protein quality control, and other subjects relevant to molecular and cellular biology. Broad ranging coverage of a key area of plant biotechnology Describes efforts to produce pharmaceutical and industrial proteins in plants Provides reviews of recent advances and technology breakthroughs Assesses realities of regulatory and cost hurdles Forward looking with coverage of small molecule technologies and the use of plants as models of human disease processes Providing wide-ranging and unique coverage, Molecular Pharming: Applications, Challenges and Emerging Areas will be of great interest to the plant science, plant biotechnology, protein science, and pharmacological communities.
Transgenic crops offer the promise of increased agricultural productivity and better quality foods. But they also raise the specter of harmful environmental effects. In this new book, a panel of experts examines: • Similarities and differences between crops developed by conventional and transgenic methods • Potential for commercialized transgenic crops to change both agricultural and nonagricultural landscapes • How well the U.S. government is regulating transgenic crops to avoid any negative effects. Environmental Effects of Transgenic Plants provides a wealth of information about transgenic processes, previous experience with the introduction of novel crops, principles of risk assessment and management, the science behind current regulatory schemes, issues in monitoring transgenic products already on the market, and more. The book discusses public involvementâ€"and public confidenceâ€"in biotechnology regulation. And it looks to the future, exploring the potential of genetic engineering and the prospects for environmental effects.
This book is open access under a CC-BY license. The importance of the pharmaceutical industry in Sub-Saharan Africa, its claim to policy priority, is rooted in the vast unmet health needs of the sub-continent. Making Medicines in Africa is a collective endeavour, by a group of contributors with a strong African and more broadly Southern presence, to find ways to link technological development, investment and industrial growth in pharmaceuticals to improve access to essential good quality medicines, as part of moving towards universal access to competent health care in Africa. The authors aim to shift the emphasis in international debate and initiatives towards sustained Africa-based and African-led initiatives to tackle this huge challenge. Without the technological, industrial, intellectual, organisational and research-related capabilities associated with competent pharmaceutical production, and without policies that pull the industrial sectors towards serving local health needs, the African sub-continent cannot generate the resources to tackle its populations' needs and demands. Research for this book has been selected as one of the 20 best examples of the impact of UK research on development. See http://www.ukcds.org.uk/the-global-impact-of-uk-research for further details.
Gathering some 90 entries from the Encyclopedia of Sustainability Science and Technology, this book covers animal breeding and genetics for food, crop science and technology, ocean farming and sustainable aquaculture, transgenic livestock for food and more.
This book explores the journey of biotechnology, searching for new avenues and noting the impressive accomplishments to date. It has harmonious blend of facts, applications and new ideas. Fast-paced biotechnologies are broadly applied and are being continuously explored in areas like the environmental, industrial, agricultural and medical sciences. The sequencing of the human genome has opened new therapeutic opportunities and enriched the field of medical biotechnology while analysis of biomolecules using proteomics and microarray technologies along with the simultaneous discovery and development of new modes of detection are paving the way for ever-faster and more reliable diagnostic methods. Life-saving bio-pharmaceuticals are being churned out at an amazing rate, and the unraveling of biological processes has facilitated drug designing and discovery processes. Advances in regenerative medical technologies (stem cell therapy, tissue engineering, and gene therapy) look extremely promising, transcending the limitations of all existing fields and opening new dimensions for characterizing and combating diseases.
This book provides an in-depth explanation of the advantages and current limitations of recombinant plant-made vaccines for use in veterinary medicine, including for livestock, pets, and wild animals. Written by top scientists in the field, it discusses the background to and latest scientific advances in plant-made vaccines for the most commonly targeted veterinary infections. With the recent high-profile research into recombinant plant-made therapeutics for Ebola and Zika viruses, it is likely that the products will be commercialized and widely used in the future. Plant-made therapeutics have a variety of advantages over those made in traditional systems; however, their most fruitful application may be in veterinary medicine, due to less stringent regulations and a greater need for low-cost products.
Molecular farming has been hailed as the "third wave" of genetically-modified organisms produced through biotechnology for the bio-based economy of the future. Unlike products of the first wave, such as herbicide resistant crop plants, which were perceived to benefit only the farmers who used them and the agrochemical companies who developed them, products of molecular farming are designed specifically for the benefit of the consumer. Such products could be purified from food or non-food organisms for a range of applications in industry, as well as animal and human health. Alternatively, the products of this technology could be consumed more directly in some edible format, such as milk, eggs, fruits or vegetables. There is a rapidly-growing interest Qn the part of the public as well as in the medical community in the role food plays in health, especially in the immunophysiological impact of food over and above the role of basic nutrition.